I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

62.4 million Indians were reported to have type 2 diabetes mellitus (T2DM) putting India on the forefront of diabetic epidemic across globe.\[[@ref1][@ref2]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref3]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref4]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref5]\] This short communication presents the results for patients enrolled from Karnataka, India.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A1chieve study: Mapping the Ibn Battuta trail

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 2243 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (82.7%) started on or switched to biphasic insulin aspart. Other groups were insulin detemir (*n* = 211), insulin aspart (*n* = 111), basal insulin plus insulin aspart (*n* = 16) and other insulin combinations (*n* = 40).

###### 

Overall demographic data

![](IJEM-17-552-g001)

After 24 weeks of treatment, overall hypoglycaemic events reduced from 0.8 events/patient-year to 0.0 events/patient-year in insulin naïve group and from 6.4 events/patient-year to 0.1 events/patient-year in insulin users group. No hypoglycaemic episode in insulin naive group at 24 weeks suggests low event rate than insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. Though blood pressure has shown a decreasing trend in the total cohort, but the finding was limited by number of observations. Quality of life improved at 24 weeks \[Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data

![](IJEM-17-552-g002)

###### 

Insulin dose

![](IJEM-17-552-g003)

All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data

![](IJEM-17-552-g004)

Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 1855 patients started on biphasic insulin aspart ± OGLD, of which 1682 (90.7%) were insulin naïve and 173 (9.3%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced for both insulin naïve (from 0.8 events/patient-year to 0.0 events/patient-year) and insulin user (from 7.7 events/patient-year to 0.1 events/patient-year) groups. Body weight decreased and quality of life improved at 24 weeks \[Table [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-552-g005)

###### 

Insulin dose

![](IJEM-17-552-g006)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-552-g007)

Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 16 patients started on basal + insulin aspart ± OGLD of which 10 (31.2%) were insulin naïve and 6 (68.8%) were insulin users. After 24 weeks of starting or switching to Basal + insulin aspart, hypoglycaemic events reduced from 4.7 events/patient-year to 0.0 events/patient-year in insulin naïve group, whereas hypoglycaemia was nil in insulin users similar to baseline. Quality of life improved after 24 weeks of treatment \[Table [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-552-g008)

###### 

Insulin dose

![](IJEM-17-552-g009)

Mean HbA~1~c and PPPG values improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for insulin naïve group. FPG values deteriorated for this group \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-552-g010)

Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 211 patients started on insulin detemir ± OGLD, of which 203 (78.5%) were insulin naïve and 8 (21.5%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 0.8 events/patient-year to 0.0 events/patient-year in insulin naïve group, whereas hypoglycaemia was nil in insulin users similar to baseline. A decrease in body weight and improvement in quality of life was also observed at the end of the study \[Table [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data

![](IJEM-17-552-g011)

###### 

Insulin dose

![](IJEM-17-552-g012)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for insulin-naïve group while mean HbA~1~c and FPG values improved in insulin users \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data

![](IJEM-17-552-g013)

Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 111 patients started on insulin aspart ± OGLD, of which 106 (95.5%) were insulin naïve and 5 (4.5%) were insulin users. After 24 weeks of starting or switching to insulin aspart, hypoglycaemic events decreased from 0.5 events/patient year to 0.0 in insulin naïve group and from 2.6 events/patient-year to 0.0 events/patient-year in insulin user group. Quality of life improved after 24 weeks of treatment \[Table [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-552-g015)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-552-g016)

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. Overall, body weight reduced in insulin naïve group and a small increase in weight was noted for insulin users. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Karnataka, India.
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